- Home
- EHC vs PCVX Comparison
EHC vs PCVX Comparison
Compare EHC & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EHC | PCVX |
|---|---|---|
| Founded | 1983 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4B | 6.0B |
| IPO Year | 1986 | 2020 |
Fundamental Metrics
Financial Performance| Metric | EHC | PCVX |
|---|---|---|
| Price | $106.75 | $46.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | ★ $141.88 | $101.67 |
| AVG Volume (30 Days) | 919.3K | ★ 1.5M |
| Earning Date | 02-05-2026 | 11-04-2025 |
| Dividend Yield | ★ 0.71% | N/A |
| EPS Growth | ★ 27.89 | N/A |
| EPS | ★ 5.29 | N/A |
| Revenue | ★ $5,795,600,000.00 | N/A |
| Revenue This Year | $11.54 | N/A |
| Revenue Next Year | $8.78 | N/A |
| P/E Ratio | $20.33 | ★ N/A |
| Revenue Growth | ★ 11.13 | N/A |
| 52 Week Low | $87.85 | $27.66 |
| 52 Week High | $127.99 | $93.77 |
Technical Indicators
Market Signals| Indicator | EHC | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 31.21 | 54.15 |
| Support Level | $106.30 | $42.40 |
| Resistance Level | $117.50 | $45.15 |
| Average True Range (ATR) | 2.29 | 1.95 |
| MACD | -0.11 | -0.30 |
| Stochastic Oscillator | 9.92 | 68.65 |
Price Performance
Historical ComparisonAbout EHC Encompass Health Corporation
Encompass Health Corp provides post-acute healthcare services in the United States through a network of inpatient rehabilitation hospitals. Inpatient rehabilitation contributes the majority of the firm's revenue and provides specialized rehabilitative treatment through a network of inpatient hospitals. These hospitals are concentrated in the eastern half of the United States and Texas.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.